Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells

被引:62
|
作者
Sonnemann, Juergen
Dreyer, Linn
Hartwig, Maite
Palani, Chithra D.
Hong, Le Thi Thu
Klier, Ulrike
Broeker, Barbara
Voelker, Uwe
Beck, James F.
机构
[1] Zentrum Kinder & Jungendmed, Abt Padiatr Onkol & Hamatol, D-17475 Greifswald, Germany
[2] Univ Greifswald, Res Ctr Pharmacol & Expt Therapeut, Greifswald, Germany
[3] Univ Greifswald, Dept Pediat Oncol Haematol, Greifswald, Germany
[4] Univ Greifswald, Lab Funct Genom, Greifswald, Germany
[5] Univ Greifswald, Dept Immunol, Greifswald, Germany
关键词
Ewing's sarcoma; histone deacetylase inhibitors; MS-275; sodium butyrate; suberoyl anilide hydroxamic acid (SAHA); TRAIL;
D O I
10.1007/s00432-007-0227-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The present in vitro study was conducted to evaluate the effects of the histone deacetylase inhibitors (HDIs) suberoyl anilide hydroxamic acid (SAHA), sodium butyrate (NaB) and MS-275 applied as single agents or in combination with TRAIL in Ewing's sarcoma. Methods Cytotoxic activities were assessed by cytofluorometric analysis of propidium iodide uptake, DNA fragmentation and mitochondrial depolarisation as well as by measuring caspase-9 and -3 activities. Cell-surface expression of TRAIL receptors was determined by cytofluorometry, and histone H4 acetylation was assessed by western blot. Results All three HDIs potently induced cell death in the two cell lines explored, SK-ES-1 and WE-68. However, they seemed to differ in their modes of action. SAHA and NaB induced mitochondrial depolarisation as well as caspase-9 and -3 activities, and their cytotoxic effects could be significantly reduced by the pan-caspase inhibitor z-VAD-fmk. MS-275 was a much weaker inducer of caspase-9 and -3 activities as well as mitochondrial injury; consistently, z-VAD-fmk had little effect on MS-275-mediated activities. Combined treatment of HDIs and TRAIL led to an additive effect in SK-ES-1 cells and a supra-additive effect in WE-68 cells. Yet, HDIs did not increase cell-surface expression of TRAIL receptor 2, but rather decreased it. Selective inhibition of caspase-8 in WE-68 cells and HDI treatment of CADO-ES-1 cells, a Ewing's sarcoma cell line deficient in caspase-8 expression, revealed that caspase-8 was not required for HDI-mediated apoptosis. Conclusions These results suggest that HDIs may be considered as a novel treatment strategy for Ewing's sarcoma either applied as monotherapy or in combination with TRAIL.
引用
收藏
页码:847 / 858
页数:12
相关论文
共 50 条
  • [1] Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells
    Jürgen Sonnemann
    Linn Dreyer
    Maite Hartwig
    Chithra D. Palani
    Le Thi Thu Hong
    Ulrike Klier
    Barbara Bröker
    Uwe Völker
    James F. Beck
    Journal of Cancer Research and Clinical Oncology, 2007, 133 : 847 - 858
  • [2] Histone deacetylase inhibitors induce caspase-dependent cell death in Ewing sarcoma cells
    Hartwig, M
    Sonnemann, J
    Dreyer, L
    Beck, JF
    KLINISCHE PADIATRIE, 2006, 218 (03): : 188 - 188
  • [3] Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells
    Sonnemann, J
    Kumar, KS
    Heesch, S
    Müller, C
    Hartwig, C
    Maass, M
    Bader, P
    Beck, JF
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 28 (03) : 755 - 766
  • [4] Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines
    Sonnemann, J
    Gänge, J
    Kumar, KS
    Müller, C
    Bader, P
    Beck, JF
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (02) : 99 - 109
  • [5] Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines
    Jürgen Sonnemann
    Jennifer Gänge
    K. Saravana Kumar
    Cornelia Müller
    Peter Bader
    James F. Beck
    Investigational New Drugs, 2005, 23 : 99 - 109
  • [6] Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
    Inoue, S
    MacFarlane, M
    Harper, N
    Wheat, LMC
    Dyer, MJS
    Cohen, GM
    CELL DEATH AND DIFFERENTIATION, 2004, 11 (Suppl 2): : S193 - S206
  • [7] Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
    S Inoue
    M MacFarlane
    N Harper
    L M C Wheat
    M J S Dyer
    G M Cohen
    Cell Death & Differentiation, 2004, 11 : S193 - S206
  • [8] HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
    Thiyam Ramsing Singh
    Sharmila Shankar
    Rakesh K Srivastava
    Oncogene, 2005, 24 : 4609 - 4623
  • [9] HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
    Singh, TR
    Shankar, S
    Srivastava, RK
    ONCOGENE, 2005, 24 (29) : 4609 - 4623
  • [10] Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
    Liu, Shuzhen
    Cheng, Hongwei
    Kwan, Wanda
    Lubieniecka, Joanna M.
    Nielsen, Torsten O.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (06) : 1751 - 1761